John Nuss Sells 21,119 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) insider John Nuss sold 21,119 shares of the business's stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the transaction, the insider now directly owns 464,582 shares of the company's stock, valued at approximately $1,096,413.52. This represents a 4.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

John Nuss also recently made the following trade(s):

• On Thursday, December 19th, John Nuss sold 13,161 shares of Ventyx Biosciences stock. The stock was sold at an average price of $2.26, for a total value of $29,743.86.

Ventyx Biosciences Price Performance

VTYX stock traded down $0.15 during trading on Monday, reaching $2.23. 1,563,354 shares of the stock traded hands, compared to its average volume of 2,039,950. The business's 50 day moving average price is $2.29 and its 200-day moving average price is $2.31. The firm has a market capitalization of $157.69 million, a PE ratio of -0.94 and a beta of 0.48. Ventyx Biosciences, Inc. has a 52-week low of $1.67 and a 52-week high of $11.48.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Oppenheimer reiterated an "outperform" rating and set a $9.00 target price (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reiterated a "neutral" rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Ventyx Biosciences currently has an average rating of "Moderate Buy" and an average target price of $10.00.

Institutional Trading of Ventyx Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Palumbo Wealth Management LLC purchased a new stake in Ventyx Biosciences during the third quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock valued at $30,000 after acquiring an additional 5,310 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Ventyx Biosciences during the 3rd quarter worth $42,000. The Manufacturers Life Insurance Company increased its holdings in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Ventyx Biosciences in the second quarter valued at about $58,000. Institutional investors and hedge funds own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.